<html xmlns="http://www.w3.org/1999/xhtml"><head>
        <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <meta name="viewport" content="width=device-width, height=device-height, initial-scale=0.5, minimum-scale=0.5, user-scalable=yes, maximum-scale=2.0, target-densitydpi=device-dpi" />
				<meta name="robots" content="all"/>
        <meta name="description" content="description">
        <meta name="keywords" content="">
        <title>Page 356 - MIMS April 2020 E4</title>
<style type="text/css">
<!--
body {
	margin-left: 0px;
	margin-top: 0px;
	margin-right: 0px;
	margin-bottom: 0px;
}
  
#container {margin:50px auto;padding:0px;width:910px;}
#left-button{ width:90px; height:100%;float:left }
#middle{ width:730px; margin:0px; float: left;}
#right-button{ width:90px; float:left;}
html, body, div, ul, li, dl, dt, dd, h1, h2, h3, h4, h5, h6, form, input, dd,select, button, textarea, iframe, table, th, td { margin: 0; padding: 0; }
img { border: 0 none; displayblock}
span,ul,li,image{ padding:0px; margin:0px; list-style:none;}
#top-title{ width:714px; margin-bottom:10px; float:left; padding:0px 8px}
#top-title2{ width:320px;  float:right;}
#content{ width: 730px; float:left;float:left;word-wrap: break-word;}
#content-top{ width:730px; background-image:url(images/top_bg.jpg); height:56px; background-repeat:no-repeat; float:left;}
#content-top1{ width:70%; padding:16px 0px 0px 30px; font-family:Arial, Helvetica, sans-serif; font-size:24px; color:#636363;float:left;}
#content-top2{ width:60px; float:right; padding:25px 30px 0px 0px;font-family:Arial, Helvetica, sans-serif; font-size:11px; color:#2f2f2f; font-weight:bold; text-align:right}
#content-middle{ width:730px; background-image:url(images/middle_bg.jpg); background-repeat:repeat-y;float:left;}
#content-middle1{ width:475px; padding:25px 0px 25px 35px; font-family:Arial, Helvetica, sans-serif; font-size:12px; color:#636363; line-height:150%;float:left;}
#content-middle2{  padding:7px; float:right; margin:25px 35px 0px 0px; border:solid 1px #c8c8c9; background-color:#FFF; text-align:center}
#content-bottom{ width:730px; background-image:url(images/bottom_bg.jpg); background-repeat:no-repeat; height:58px;float:left;}
#content-bottom2{ width:110px; height:42px; margin:0px auto; padding-top:4px;}
#input{ width:58px; height:20px; background-color:#FFF; border:solid 1px #dfdfe0; color:#636363; text-align:center; font-size:11px;}
.font1{ font-family:Arial, Helvetica, sans-serif; font-size:10px; color:#2f2f2f;}
.font1 a:link{
	text-decoration: none;
    color:#2f2f2f;

}
.font1 a:visited{
	text-decoration: none;
    color:#2f2f2f;
	
}
.font1 a:hover{
	color: #2f2f2f;
	text-decoration: underline;

}



.text-container {
padding: 20px;
color: #333;
margin-top: 24px;
line-height: 22px;
border-top-left-radius: 3px;
border-top-right-radius: 3px;
}

.use-as-video {
float: right;
padding-left: 20px;
}
.cc-float-fix:before, .cc-float-fix:after {
content: "";
line-height: 0;
height: 0;
width: 0;
display: block;
visibility: hidden;
}
.use-as-video-img {
cursor: pointer;
position: relative;
width: 320px;
height: 180px;
}
.use-as-video-title {
font-size: 15px;
font-weight: bold;
color: #000000;
padding-bottom: 5px;
}
-->
</style>
<script type="text/javascript">
<!--
function MM_preloadImages() { //v3.0
  var d=document; if(d.images){ if(!d.MM_p) d.MM_p=new Array();
    var i,j=d.MM_p.length,a=MM_preloadImages.arguments; for(i=0; i<a.length; i++)
    if (a[i].indexOf("#")!=0){ d.MM_p[j]=new Image; d.MM_p[j++].src=a[i];}}
}

function MM_swapImgRestore() { //v3.0
  var i,x,a=document.MM_sr; for(i=0;a&&i<a.length&&(x=a[i])&&x.oSrc;i++) x.src=x.oSrc;
}

function MM_findObj(n, d) { //v4.01
  var p,i,x;  if(!d) d=document; if((p=n.indexOf("?"))>0&&parent.frames.length) {
    d=parent.frames[n.substring(p+1)].document; n=n.substring(0,p);}
  if(!(x=d[n])&&d.all) x=d.all[n]; for (i=0;!x&&i<d.forms.length;i++) x=d.forms[i][n];
  for(i=0;!x&&d.layers&&i<d.layers.length;i++) x=MM_findObj(n,d.layers[i].document);
  if(!x && d.getElementById) x=d.getElementById(n); return x;
}

function MM_swapImage() { //v3.0
  var i,j=0,x,a=MM_swapImage.arguments; document.MM_sr=new Array; for(i=0;i<(a.length-2);i+=3)
   if ((x=MM_findObj(a[i]))!=null){document.MM_sr[j++]=x; if(!x.oSrc) x.oSrc=x.src; x.src=a[i+2];}
}
//-->
</script>
</head>

<body onload="MM_preloadImages('images/next2.png','images/previous2.png')">
<div id="container">
<div id="left-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page355.html"><img src="images/previous_big.png" width="90" height="80" /></a></p>
</div>
<div id="middle">
  <div id="top-title"><span class="font1">Basic HTML Version</span>
    <div id="top-title2">
      <table width="100%" border="0" align="right" cellpadding="0" cellspacing="0">
        <tr>
        	<td width="66%"> </td>
          <td width="35%" style="display:none" align="right"><img src="images/content.png" width="19" height="16" /></td>
          <td width="31%" style="display:none" class="font1"><a href="">Table of Contents</a></td>
          <td width="6%"><img src="images/view.png" width="19" height="16" /></td>
          <td width="28%" class="font1"><a href="../../MIMS April 2020 E4.html#p=356">View Full Version</a></td>
        </tr>
      </table>
    </div>
  </div>
  <div id="content">
     <div id="content-top">
        <div id="content-top1">Page 356 - MIMS April 2020 E4</div>
        <div id="content-top2">P. 356</div>
     </div>
     <div id="content-middle">
     	
     	  <div class="text-container">
    <div class="use-as-video cc-float-fix">
      <a style="text-decoration: none;" href="../../MIMS April 2020 E4.html#p=356"><img src="../thumb/356.jpg" /></a>
    </div>

    <p class="use-as-video-title"></p>
    <pre style="white-space:pre-line"><code>Special Foods / Cytostatics - 22 / 23                                          2020-04 / 319
       Drug interactions: Heparin in clin.dos.caus. trans. lipoprot.li-  (S4) SOL.FOR INJ. T/26/63, 64, 57, W/26/386.  718135-001: 100 mg, 5, R2 228,68
       pase releas.into circulat.result.in init.incr.plasma lipolys.follow.by   782548-009: 25 mg/ml, 1x2 ml vial, R40,92  718136-001: 250 mg, 5, R5 338,10
       trans.triglycer. clear.decr, soybean oil may interf.with therap.eff.   782556-019: 25 mg/ml, 1x20 ml vial, R150,96  For further details refer to manufact.prod.lit.
       of coumarin derivativ.        782564-003: 1 g/10 ml, 1x10 ml vial, R588,51  ACCORD VINCRISTINE, Accord [P/S]
       NUTRIFLEX LIPID SPECIAL WITHOUT   701110-001: 5 g/50 ml, 1x50 ml vial, R3 262,78  Vincristine sulphate.
                                     (S4) TABS. 37/26/0466. 2,5 mg.
       ELECTROLYTES, B Braun [P/S]   Indications: Ac.lymphoblast.leukaem.in childr.& mening.leukem.,   Indications: Ac.leukaem.in combin.with other agents, Hodgkin’s
       Each 1250 ml contains: Glucose (anhydr.) 180,0 g equiv. to glucose   chorio Ca & relat.trophoblast. tumours of women, women with   dis.& relat.lymphomas, other neoplasms esp.Wilm’s tumour, neuro-
       monohydr. 198,0 g; Medium-chain triglycerides 25,0 g; Soybean oil   non-metastat. trophoblast.dis., hydatidiform mole & chorioad-  blastoma, brain tumours, rhabdomyosarcoma, Ca of breast, bladder
       25,0 g; Isoleucine 4,11 g; Leucine 5,48 g; Lysine monohydrate 4,47   enoma destruens, breast/tong./pharynx/ testis Ca in conjuct.with   & male/female reproduct.syst.
       g equiv.to lysine 3,98 g; Methionine 3,42 g; Phenylalanine 6,15 g;   chlorambucil & dactinomycin, lung Ca & osteogen.sarcomas, sev.   (S4) SOL.FOR INJ. 41/26/1002
       Threonine 3,18 g; Tryptophan 1,00 g; Valine 4,51 g; Arginine 4,73 g;   psorias., bone marrow transpl.graft versus host react.prophylax.,   713432-001: 1 mg/ml, 1x2 ml vial, R123,27
       Histidine 2,19 g; Alanine 8,49 g; Aspartic acid 2,63 g; Glutamic acid   dermatomyositis, rheumat. arthrit. not adeq.respond.to other ther.,   For further details refer to manufact.prod.lit.
       6,14 g; Glycine 2,89 g; Proline 5,95 g; Serine 5,25 g.  Wegener’s granulomatos., pityrias.rubra pilaris.
       Each 1875 ml contains: Glucose (anhydr.) 270,0 g equiv. to glucose   712504-001: 100, R150,45  ADCETRIS, Takeda
       monohydr. 297,0 g; Medium-chain triglycerides 37,5 g; Soybean oil   For further details refer to manufact.prod.lit.  Brentuximab vedotin
       37,5 g; Isoleucine 6,16 g; Leucine 8,22 g; Lysine monohydrate 6,71   Indications: Relapsed/refractory Hodgkin lymphoma (HL) & re-
       g equiv.to lysine 5,97 g; Methionine 5,13 g; Phenylalanine 9,22 g;   ABRAXANE, Key Oncologics [P/S]  lapsed/refractory system. anaplastic large cell lymphoma (sAL-
       Threonine 4,76 g; Tryptophan 1,50 g; Valine 6,76 g; Arginine 7,09 g;   Paclitaxel.  CL) in adults.
       Histidine 3,28 g; Alanine 12,73 g; Aspartic acid 3,94 g; Glutamic acid   Indications: Metastat.breast Ca aft.combinat. chemother. fail./re-  (S4) CONC.FOR SOL.FOR INFUS., 48/26/0433.
       9,20 g; Glycine 4,33 g; Proline 8,93 g; Serine 7,88 g.  lapse within 6 mnths of adjuv. chemother. (prev.chemother.should   723473-001: 50 mg/vial, 1x10 ml, R31 645,08
       Each 2500 ml contains: Glucose (anhydr.) 360,0 g equiv. to glucose   have incl.an anthracycline unless clinic.C/I), first-line treatm of non-  For furth.details refer to manufact.prof.info.
       monohydr. 396,0 g; Medium-chain triglycerides 50,0 g; Soybean oil   small cell lung Ca in combinat.with carboplatin when curat.surg.and/  AFINITOR, Novartis South Africa (Pty) Ltd
       50,0 g; Isoleucine 8,21 g; Leucine 10,96 g; Lysine monohydrate 8,94   or radiat.not applic., first-line treatm of local.advanc. unresectable/   See Section 24.1
       g equiv.to lysine 7,96 g; Methionine 6,84 g; Phenylalanine 12,29 g;   metastat.adenocarcinoma of pancreas. in combin.with gemcitabine.
       Threonine 6,35 g; Tryptophan 2,00 g; Valine 9,01 g; Arginine 9,45 g;   (S4) POWD.FOR INJ. 50/26/0182.  ALIMTA 500 MG, Eli Lilly [P/S]
       Histidine 4,38 g; Alanine 16,98 g; Aspartic acid 5,25 g; Glutamic acid   718697-001: 100 mg, 1x20 ml, R7 121,44  Pemetrexed
       12,27 g; Glycine 5,78 g; Proline 11,90 g; Serine 10,50 g.   For further details refer to manufact.prod.lit.  Indications: Malign.pleur.mesothelioma in combinat. with cisplatin,
       Indications: Supply of dly. requirem.of energy, essent. fatty acids,   ACCORD CARBOPLATIN, Accord [P/S]  init.treatm.of loc.advanc. metastat.non-small cell lung Ca other than
       amino acids & fluids dur. parenter.nutrit.for pts. with mild to mod.  Carboplatin.  predom. squamous cell histol.in combinat.with cisplatin, monother.
       sev. catabol.when oral/enter. nutrit.imposs./ insuffic/contraindicat.  Indications: Advanc.ovarian Ca of epithelial origin in 1  line ther.  in loc.advanc./metastat. adenocarcinoma of the lung aft.prior chem-
                                                            st
       (S3) IV INFUS. 41/25/0760.    or 2  line ther.aft.fail.of other treatm., small cell lung Ca, squamous   other., monother.for maint.treatm.of loc.advanc./ metastat. lung ad-
                                      nd
       716317-001, 1 250 ml, R936.30  cell Ca of head and neck.   enocarcinoma when dis.has not progress.immed.aft.std.chemother.
       716319-001, 1 875 ml, R1 404,46  (S4) INJ. 41/26/0435. 10 mg/ml  (S4) POWD.FOR SOL.FOR INFUS. 39/26/0028. 25 mg/ml.
       716321-001, 2 500 ml, R1 872,63  711367-001: 1x15 ml vial, R300,92  705833-001: 1x500 mg vials, R11 491,14
       Dosage: For IV infus., admin.continuous.at max. infus.rate of 1,7 ml/  711368-001: 1x45 ml vial, R902,58  For further details refer to prof info.
       kg body weight/hr, individ. dose accord.to pt.requirm.  For furth.details refer to manufact.prod.lit.
       Max.dly.dose: 35 ml/kg body weight.                        ALKERAN, (Aspen Pharmacare: Pharma) Pharmacare [P/S]
       Ref.to prod.lit.for sol.prep.  ACCORD EPIRUBICIN, Accord [P/S]  Melphalan.
       Contraindications: Disturbs. of amino acid/lipid metabol., hypoka-  Epirubicin  Indications: Multiple myeloma, advanc.ovar. adenocarcinoma,
       laem., hyponatraem., unstab. metabol. e.g. sev.post aggress.syndr./  Indications: Mono chemother.for breast & gastr. Ca, malign.lym-  adjuv.in breast Ca.
       unstabilis. coma of unknown orig., hyperglycaem.not respond. to   phoma, soft-tiss.sarcoma., advanc. colorect.Ca, malign.melanoma.,   (S4) TABS, [P/S] H/26/2744.
       insul.doses up to 6 unit insul./hr., acidos., intrahepat. cholestas.,   combinat.ther. with other chemotherapeut.agents for lung & ovar. Ca.  701998-008: 2 mg, 25, R648,48
       sev.hepat./ren.insuffic., manifest card.insuffic., aggravat.haemor-  (S4) SOL.FOR INJ. 2 mg/ml, 42/26/0153, 0900  (S4) INJ, [P/S] 27/26/0506
       rh. diathes., acute myocard.infarct.& stroke/ thromboembol./ lipid   716228-001: 10 mg, 1 x5 ml vial, R132,16  Indications: Multiple myeloma, ovar.Ca, neuroblastoma in child-
       embol., known hypersens.to egg/ soy prot., childr. &lt; 2yrs, unstable   716239-001: 50 mg, 1x25 ml vial, R660,84  hood.
       circulat. stat., inadeq.cellul. O2 supply, fluid overload/ overhydrat.,   For further details refer to manufact.prod.lit.  797774-009: 50 mg/vial & solv.dil., R661,45
       electrolyt./fluid bal.disturb., ac.pulm. oed. /decompensat.card.insuf-  ACCORD GEMCITABINE, Accord [P/S]  For further details refer to manufac.prod.lit.
       fic., pregn.& lactat. as safety & effic.not est.  Gemcitabine HCl.  ASPEN CARBOPLATIN, (Aspen Pharmacare) Pharmacare [P/S]
       Side effects: Flush., incr.temp., cold feel., shiver., headache, loss   Indications: Loc.advanc./metastat.non-small cell lung Ca, 1st line   Carboplatin.
       of appet., hyperglycaem., bld. disords., N&V, resp.distr., back/chest/  treatm.in loc.advanc.(non-resect. stage II or III) or metast.(stage IV)   Indications: Advanc.ovarian Ca of epithelial origin in 1  line ther.
                                                                                          st
       bone/ lumb. area pain, BP chang., hypersens.reacts, cyanos., throm-  pancreas adenocarcinoma prev.treat.with 5-FU, transit.cell bladd. Ca,   or 2  line ther.aft.fail.of other treatm., small cell lung Ca, squamous
                                                                    nd
       bophlebit., septicaemia, loc.irrit.at inj.site, overload. syndr., hyper-  unresect./loc.recurr./metastat.breast Ca combin.with paclitaxel in   cell Ca of head and neck.
       hydrat., pulm.oed.            pts.who have relaps. follow. adjuv./neo-adjuv.ther.where prior chem-  (S4) CONC.FOR SOL.FOR INFUS. 41/26/0609, 0610 10 mg/ml
       Special precautions: Monit.pts.on coumarin derivats. closely, do   other. incl.an anthracycl.unless C/I, alone/in combinat.for recurr.epi-  720402-001: 150 mg, 1x20 ml vial, R339,71
       not mix/infuse concomit.with other sols., caut.in cases of incr.ser.  thel.ovar.Ca pts.who have relaps. follow.platin.-based chemother.  720403-001: 450 mg, 1x50 ml vial, R1 019,13
       osmolarit./ imp. card.or ren.funct., monit./correct disturbs.of fluid,   (S4) POWD.FOR SOL.FOR INFUS. 42/26/0088, 0903  For furth.details refer to manufact.prod.lit.
       electrol./acidbase bal.bef.start of infus., rapid infus.can lead to   713874-001: 200 mg, 1x10 ml vial, R303,09
       fluid overload with patholog. ser.electrol.conc./hyperhydrat./pulm.   713873-001: 1 g, 1x50 ml vial, R1 572,75  ASPEN EPIRUBICIN, (Aspen Pharmacare: Pharma)
       oed., monit.ser.triglycer./bld.gluc.conc., interrupt infus. with S&S of   For furth.details refer to manufact.product lit.  Pharmacare [P/S]
       anaphylact.react., reduc/ interrupt dos.if bld.gluc.conc.&gt;14 mmol/L   Epirubicin
       (250 mg/ dl), suppl.appropr.replacem.of trace elem.& vits. dur. long-  ACCORD IRINOTECAN, Accord [P/S]  Indications: Mono chemother.for breast & gastr. Ca, malign.
       term.admin., do not giv.simultan.with bld. in same infus.set., fat cont.  Irinotecan HCl trihydrate.  lymphoma, soft-tiss.sarcoma., advanc. colorect.Ca, malign.mela-
       may interf.with cert. lab.meas.  Indications: Advanc.colorect.Ca with WHO perform. status of 2   noma., combinat.ther. with other chemotherapeut.agents for
       Drug interactions: Heparin in clin.dos.caus. trans. lipoprot.lipase   or low.in combinat.with 5-fluorouracil and folinic acid without prior   lung & ovar. Ca.
       releas.into circulat.result.in init. incr.plasma lipolys.follow.by trans.  chemother. for advanc.dis.or as sngl.agent when est. 5-fluorouracil   (S4) POWD.FOR SOL.FOR INJ. 42/26/0018, 0019
       triglycer. clear. decr, soybean oil may interf.with therap.eff. of cou-  contain.regim.has fail.  714218-001: 10 mg, 1 vial, R186,00
       marin derivativ.              (S4) INJ. 41/26/1004, 0025. 20 mg/ml.  714219-001: 50 mg, 1 vial, R785,78
                                     712603-001: 40 mg/2 ml vial, R404,11  (S4) SOL.FOR INJ. 42/26/0528, 0530
                                     712872-001: 100 mg/5 ml vial, R1 010,29  714241-001: 10 mg, 1 vial, R144,31
                                     For further info.refer to manuf.product lit.  714220-001: 50 mg, 1 vial, R721,56
       23     CYTOSTATICS            ACCORD PACLITAXEL, Accord [P/S]  For further details refer to manufact.prod.lit.
              (See also 19.6.3, 19.8)  Paclitaxel.                ASPEN ETOPOSIDE 100 mg/5 ml, (Aspen Pharmacare:
                                     Indications: Palliat.treatm.of stage 3/4 advanc. loc.ovar.Ca aft.
       HALAVEN (MDR Listing)         surg.resect.in combinat.with cisplatin, palliat.managem.of met-  Pharma) Pharmacare [P/S]
                                                                  Etoposide.
       REVOLADE (MDR Listing)        astat.ovar.Ca aft.fail.of first line/subseq.chemother., metastat.
       RIBOMUSTIN (MDR Listing)      breast Ca aft.combinat.chemother.fail./relapse within 6 mnths   Indications: Testic.tumours/breast & small cell lung Ca in com-
                                                                  binat.with other approv. chemotherapeut. Agents, non-Hodgkin’s
       SPRYCEL (MDR Listing)         of adjuvant chemother.(prev. chemother. should have incl.an an-  lymphomas, ac.non-lymphocyt.leukaem., Kaposi’s sarcoma as-
       SUTENT (MDR Listing)          thracycline unless clinic.C/I), first line ther.of advanc./ metastat.
       TASIGNA (MDR Listing)         breast Ca in combin.with trastuzumab in pts. who over-express   soc.with AIDS.
                                                                  (S4) SOL FOR INFUS. 42/26/0017. 100 mg/5 ml.
       VOTRIENT (MDR Listing)        HER-2 at a 2+ or 3+ lev.as determin. by immunohistochemistry,
       XALKORI (MDR Listing)         palliat.treatm. of advanc.non-small cell lung Ca when curat.surg.   719861-001: 1x5 ml vial, R208,48
       XTANDI (MDR Listing)          and/ or radiat. not applic.  For further details refer to manufact.prod.lit.
       YERVOY (MDR Listing)          (S4) SOL FOR INJ. 44/26/0377, 0378, 0379. 6 mg/ml  ASPEN-VINORELBIN, (Aspen Pharmacare: Pharma)
                                     720614-001: 30 mg, 1x5 ml vial, R133,70
       ABIC VINCRISTINE, (Cipla Medpro) Teva [P/S]  720616-001: 100 mg, 1x16,7 ml vial, R446,58  Pharmacare [P/S]
       Vincristine sulphate.         720617-001: 300 mg, 1x50 ml vial, R1 337,06  Vinorelbine tartr.
       Indications: Ac.leukaem., Hodgkin’s dis.& rel. lymphomas.  For further details refer to manufact.prod.lit.  Indications: Palliat.treatm.of advanc.inoper.non-small cell lung Ca
       (S4) SOL.FOR INJ. T/26/221, W/26/241. 1 mg/ml.             as a sngl.agent or in combinat. Combinat.ther.proves more effect. st
       753971-003: 1 ml vial, R92,75  ACCORD TEMOZOLOMIDE, Accord [P/S]  than monother. Metastat.breast Ca in pts.where anthracycline 1
       785202-005: 2 ml vial, R197,53  Temozolomide               line monother.has fail.or who have relaps.within.6 mnths.of anthra-
       For further details refer to manufact.prod.lit.  Indications: Recurr.malign.glioma, advanc. metast. malign.  cycline-based adjuv.ther.
                                     melanoma.                    (S4) CONC.SOL.FOR INFUS. 42/26/0020, 0021. 10 mg/ml.
       ABITREXATE, (Cipla Medpro) Teva [P/S]  (S4) CAPS. 44/26/0960, 0961, 0962, 0963  715822-001: 10 mg, 10x1 ml sngl.dos.vials, R3 481,17
       Methotrexate.                 718133-001: 5 mg, 5, R111.45  715821-001: 50 mg, 1x5 ml sngl.dos.vial, R1 740,58
       Indications: Gen.oncology, ac.lymph.in childr., ac. pustul.psorias.  718134-001: 20 mg, 5, R445,75  For further details refer to manufact.prod.lit.</code></pre>
     	</div>
    
     </div>
     <div id="content-bottom">
       <div id="content-bottom2">
         <table width="110" border="0" cellspacing="0" cellpadding="0">
           <tr>
             <td width="22%" height="44"><a href="page355.html"><img src="images/previous.png" width="26" height="19" id="Image2" onmouseover="MM_swapImage('Image2','','images/previous2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
             <td width="43%">
             	&nbsp;&nbsp;&nbsp;<a href="page351.html">351</a>&nbsp;&nbsp;&nbsp;<a href="page352.html">352</a>&nbsp;&nbsp;&nbsp;<a href="page353.html">353</a>&nbsp;&nbsp;&nbsp;<a href="page354.html">354</a>&nbsp;&nbsp;&nbsp;<a href="page355.html">355</a>&nbsp;&nbsp;&nbsp;<a href="page356.html">356</a>&nbsp;&nbsp;&nbsp;<a href="page357.html">357</a>&nbsp;&nbsp;&nbsp;<a href="page358.html">358</a>&nbsp;&nbsp;&nbsp;<a href="page359.html">359</a>&nbsp;&nbsp;&nbsp;<a href="page360.html">360</a>&nbsp;&nbsp;&nbsp;<a href="page361.html">361</a>
             </td>
             <td width="35%"><a href="page357.html"><img src="images/next.png" width="26" height="19" id="Image1" onmouseover="MM_swapImage('Image1','','images/next2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
           </tr>
         </table>
       </div>
     </div>
  </div>
</div>
<div id="right-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page357.html"><img src="images/next_big.png" width="90" height="80" /></a></p>
</div>


</div>

</body>
</html>
